Mirabegron is a first-generation selective β3-AR agonist approved for overactive bladder syndrome with a daily dose of 50 mg; thus, the effects of high mirabegron doses on human adipose tissue might be mediated through β1-AR and not by selective activation of β3-AR, as evidenced by the off-target effects, such as tachycardia, reported in these clinical trials (Malik et al. 2012). Here, ADRB3 is linked to Urinary urgency.